NeoVirTech

We are pleased to announce the creation of a platform dedicated to oncolytic viruses, to accelerate the time-to-market for your oncolytic viruses, from design to pre-clinical development! Don't hesitate to contact us for more information!  contact@neovirtech.com #virus #oncology #oncolytic

Breakthrough ! Human papillomavirus (HPV18) live cell visualization in dividing keratinocytes using ANCHOR technology. HPV genome in green (spots), nuclei in blue, microtubules in red. Wonderful work from Alison McBride’s laboratory at the NIAID. HPV is associated with common warts but also several cancers. Until now, how HPVs are maintained in proliferating cells was not directly visualized. Another example of the power of the ANCHOR technology to investigate the biology of viruses and viral vectors. More information: contact@neovirtech.com https://lnkd.in/e5uxkYqi #HPV #papillomavirus #microscopy #livecell #ANCHOR #virus

Our colleague Pierre Cordelier is actively recruiting for the Perseverance project. See below. We are seeking to recruit in October/November 2024 a qualified research engineer for the development of an innovative theranostic platform for anticancer virotherapy (PERSEVERANCE). This specific part of the project, funded by BPI France and the Occitanie region, will focus on the establishment, culture, preservation, and analysis of organoids derived from solid tumors with poor prognosis, before and after infection by oncolytic viruses, candidates for clinical transfer. This public-private project is integrated into the recognized expertise of the research team in the transfer of innovative biotherapy for cancer treatment, in close collaboration with the National Veterinary School of Toulouse, clinical services of the Cancer University Institute of Toulouse and industry (Imactiv-3D, NeoVirTech). Main activities: Creation of 3D cell models such as organoids from patient tumors, 3D culture of cancer cells, treatment and monitoring of in vitro experimental models treated with oncolytic viruses and other active molecules, internal training on the principles and implementation of experimental techniques, supervising users, particularly students, and managing the technical resources allocated to experimental activities. Required knowledge: Cellular biology, with mandatory prior experience in the production and 3D culture of primary cells, various analyses (Immunohistochemistry, immunofluorescence, transcriptomics), and project management. Level: Master’s, PhD Duration: 24 months. Application deadline: 07/10/2024. Environment: The project will be carried out within the ImPACT team (Therapeutic Innovation in Pancreatic Cancer, https://lnkd.in/eMRCg5re) at the Cancer Research Center of Toulouse (CRCT, https://lnkd.in/eK-3RnsF), under the supervision of Dr. Pierre Cordelier (contact: pierre.cordelier@inserm.fr, CV + cover letter).

📖 Découvrez le book « CATRIEM » du Réseau SATT, réalisé par PULSALYS, qui s’engage dans la lutte contre les Maladies Infectieuses Emergentes (MIE) et les Menaces Nucléaires, Radiologiques, Biologiques et Chimiques (NRBC) ➡ https://lnkd.in/d2-jBDXq 👀 Découvrez ce book qui a l'ambition de présenter le consortium CATRIEM, fournir les éléments clés du marché, évoquer les enjeux des filières, de donner la parole à des experts clés du domaine et surtout à identifier de nouveaux projets ambitieux sur la thématique des Maladies Infectieuses Emergentes. 💡 L’ambition de CATRIEM est de sélectionner des projets innovants, compétitifs à l’échelle internationale, visant à développer des produits médicaux (agents de thérapie, biomarqueurs, …) ou non médicaux (équipements de protection, agents désinfectants, …) afin de mieux se préparer aux prochaines émergences épidémiques et menaces NRBC. 🙏 Un grand MERCI à l'ensemble des personnes interviewées : Anne Jouvenceau-Bester, Agence de l'innovation en santé ; Pascale Auge, Inserm Transfert ; Hervé Raoul ; Benjamin Roche ; Manuel Rosa-Calatrava, CIRI Centre International de Recherche en Infectiologie ; Stephane Cauchi, Institut Pasteur de Lille ; Alexandre Pachot, Hospices Civils de Lyon - HCL ; Tara DUONG, AP-HP, Assistance Publique - Hôpitaux de Paris ; Xavier Lescure ; Jérôme Sallette, CERBA HEALTHCARE ; Alexandre Le Vert, Osivax ; Franck Gallardo, NeoVirTech ; Xavier Morge, BIOASTER ; Florence Agostino Etchetto, Lyonbiopôle Auvergne-Rhône-Alpes et Sophie Jullian 📌 Pour rappel, le Consortium d’Accélération et de Transfert pour la Réponse aux Infections Emergentes et aux Menaces (CATRIEM), lauréat de l’appel à projets "Maturation-Prématuration" de l'Etat dans le cadre de #France2030 vise à : 🎯 intensifier et renforcer la chaine d’accompagnement de projets d’innovation à fort potentiel 🎯 accélérer leur transfert vers le monde socio-économique, au bénéfice de la Stratégie Nationale d’Accélération Maladies Infectieuses Emergentes et Menaces Nucléaires (SNA MIE-MN). 🔥 Pour + d'infos et pour télécharger le book, c'est ici ➡ https://lnkd.in/d2-jBDXq Anne GUYON Catherine DAUMAS Clement Minez Ministère de l'Enseignement supérieur et de la Recherche Secrétariat général pour l'investissement ANRS Maladies infectieuses émergentes Inserm Inserm Auvergne-Rhône-Alpes Eglantine Rollet Jean-Michel Gauthier Séverine BARTH (Beaucourt) Sandrine Ayuso

We are pleased to announce that as part of their strategic partnership, NeoVirTech and VirHealth offer a wide range of tests to evaluate the efficiency of disinfectants and disinfection equipment on MPOX mimetic viral strains: product efficiency screening with the VACV ANCHOR system, standardized tests according to EN/ASTM/ISO standards, coating/materials/textiles tests and R&D studies according to client’s specifications. Contact us to know more: contact@neovirtech.com ; contact@virhealth.fr

Very proud to see that our article describing the formulation of the LAVR-289 as a liquid crystal emulsion was published in International Journal of Pharmaceutics. LAVR-289 is a new acyclonucleoside phosphonate with nanomolar broad spectrum antiviral activities. This work has been done in collaboration with L. Agrofoglio Team at the Institut de Chimie Organique et Analytique - ICOA UMR7311. We thank the Agence de l'innovation de défense for funding of the study (RAPID DENALPOVIR n°192906106).

NeoVirTech and VirexpR have joined forces to develop an experimental test bench model of airborne contamination by poxviruses “On 14 August, the WHO declared an international public health emergency in response to the growing number of human infections by the monkeypox virus, which could be transmitted by contact, fomites and bioaerosols. This declaration was followed by the publication of Mpox global strategic preparedness and response plan on August 26th” The VACV ANCHOR poxvirus, developed by NeoVirTech and labeled “used by French Armed Forces” in 2024, is the mimetic model operated by VirexpR to characterize infectious bioaerosols using various test benches with the aim of evaluating the performance of air treatment and analysis technologies and devices under real conditions of use. NeoVirTech, a biotechnology company developing autofluorescent virus for antiviral discovery and measurement of disinfection procedure, works on poxviruses of human and animal source since more than 10 years. VirexpR is a service company committed to improving the Indoor Air Quality of confined spaces and contributing to national and European sovereignty in terms of protection against emerging and re-emerging infectious diseases. More information : contact@virexpr.fr www.virexpr.fr contact@neovirtech.com www.neovirtech.com #Monkeypox #Poxvirus #Anchor #IAQ #Bioaerosol #contamination #fomite

Our new article describing the use of the ANCHOR system to visualize African Swine Fever Virus infection and replication in living cells has been published in antiviral research. Congrats to all authors. For informations: contact@neovirtech.com #AFSV #africanswine #swine #microscopy #virus #antivirals

We're proud to announce that our VACV (vaccinia virus) Anchor virus is now UAF (used by armed forces) approved! THE best way to accelerate development of your disinfection or antiviral solutions! Don't hesitate to contact us for more information! #virus #VACV #poxvirus

Our patent describing the visualization of the retrotranscription of viral DNA genomes (namely HIV) in living cells has been delivered in Europe. This work is a fruitful collaboration between NeoVirTech and Institut Pasteur. #HIV #VIH #AIDS #SIDA #virus